SAS Analytics Empowers Researchers to Easily Manage Data in the Cloud
SAS Life Science Analytics Framework helps pharmaceutical, biotechnology, and medical device manufacturers effortlessly gather, standardize, and analyze research data from start to finish
Analytics leader SAS has developed software to help clinical researchers instantly query and analyze data in the cloud. With the new offering, biopharmaceutical organizations can improve the efficiency and productivity of clinical research and speed lifesaving therapies and devices to market.
SAS® Life Science Analytics Framework combines features of SAS Drug Development and SAS Clinical Data Integration to provide a single, integrated analytics foundation for clinical research. The solution delivers three key efficiencies:
- Provides a repository optimized for data standards management.
- Eases the burden of project management through easier workflows.
- Streamlines access to analytics.
“From an information management perspective, the world is becoming an order of magnitude more complex, with highly challenging, diverse data security and regulatory compliance process requirements,” said Alan Louie PhD, Research Director, IDC Health Insights. “As a result, R&D is undergoing a significant transformation as companies seek to improve the efficiency of their new drug development. SAS is well poised with its latest software to help customers get the most value from their clinical research data.”
Cloud computing
For more than a decade, SAS has been securely hosting clinical research solutions for life science companies in the cloud. This offering builds on that track record.
“Data is the rocket fuel for innovation in life sciences,” said Graham Hughes, MD, Chief Medical Officer of the SAS Center for Health Analytics and Insights. “Anything that speeds up the process of data analysis is usually rapidly embraced by our customers, and SAS’ cloud-based Life Science Analytics Framework does just that by reducing deployment time and technical complexity for customers, while providing reliable access to the most widely adopted analytic tools in the industry.”
SAS will demonstrate its life sciences products in Booth 1323 during the DIA 2014 Annual Meeting in San Diego, June 16-18. Learn more about SAS Life Science Analytics Framework and read Deploying an Analytics Foundation for Clinical Research.
About SAS® for health analytics
SAS for health analytics encompasses the technologies and skills needed to deliver best-in-class solutions for improving medical care, strengthening financial performance, deepening customer relationships and pursuing medical innovations. For more than three decades, leading life sciences companies such as AstraZeneca, Janssen Pharmaceuticals and PSKW have relied on SAS Analytics for drug discovery, clinical trials, sales and marketing, and manufacturing. Visit SAS® for Life Sciences for more information.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
